Moleculin Biotech Inc

Company Profile

Moleculin Biotech Inc had its IPO on 2016-06-02 under the ticker symbol MBRX.

The company operates in the Healthcare sector and Biotechnology industry. Moleculin Biotech Inc has a staff strength of 15 employees.

Stock update

Shares of Moleculin Biotech Inc opened at $0.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.4 - $0.45, and closed at $0.41.

This is a +2.24% increase from the previous day's closing price.

A total volume of 70,220 shares were traded at the close of the day’s session.

In the last one week, shares of Moleculin Biotech Inc have slipped by -25.72%.

Moleculin Biotech Inc's Key Ratios

Moleculin Biotech Inc has a market cap of $11.95 million, indicating a price to book ratio of 0.6616 and a price to sales ratio of 0.

In the last 12-months Moleculin Biotech Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-30774000. The EBITDA ratio measures Moleculin Biotech Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Moleculin Biotech Inc’s operating margin was 0% while its return on assets stood at -32.09% with a return of equity of -54.91%.

In Q2, Moleculin Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Moleculin Biotech Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.82 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Moleculin Biotech Inc’s profitability.

Moleculin Biotech Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3931. Its price to sales ratio in the trailing 12-months stood at 0.

Moleculin Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$47.12 million

Total Liabilities

$6.55 million

Operating Cash Flow

$0

Capital Expenditure

$15000

Dividend Payout Ratio

0%

Moleculin Biotech Inc ended 2024 with $47.12 million in total assets and $0 in total liabilities. Its intangible assets were valued at $47.12 million while shareholder equity stood at $40.27 million.

Moleculin Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $6.55 million in other current liabilities, 30000.00 in common stock, $-115726000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.17 million and cash and short-term investments were $32.17 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Moleculin Biotech Inc’s total current assets stands at $35.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $12000.00 compared to accounts payable of $4.14 million and inventory worth $-12000.00.

In 2024, Moleculin Biotech Inc's operating cash flow was $0 while its capital expenditure stood at $15000.

Comparatively, Moleculin Biotech Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.41

52-Week High

$1.52

52-Week Low

$0.3377

Analyst Target Price

$8

Moleculin Biotech Inc stock is currently trading at $0.41 per share. It touched a 52-week high of $1.52 and a 52-week low of $1.52. Analysts tracking the stock have a 12-month average target price of $8.

Its 50-day moving average was $0.59 and 200-day moving average was $0.9 The short ratio stood at 1.87 indicating a short percent outstanding of 0%.

Around 322.9% of the company’s stock are held by insiders while 1022.7% are held by institutions.